Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted): 2014-2016
- Soleno Therapeutics' EPS (Weighted Average and Diluted) rose 86.88% to -$0.21 in Q2 2016 from the same period last year, while for Jun 2016 it was -$0.75, marking a year-over-year increase of 51.26%. This contributed to the annual value of -$4.38 for FY2024, which is 85.59% down from last year.
- According to the latest figures from Q2 2016, Soleno Therapeutics' EPS (Weighted Average and Diluted) is -$0.21, which was up 86.88% from -$1.60 recorded in Q2 2015.
- Over the past 5 years, Soleno Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.21 during Q2 2016, and registered a low of -$1.60 during Q2 2015.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$1.12, with a median of -$1.56 in 2014.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first decreased by 2.56% in 2015, then skyrocketed by 86.88% in 2016.
- Quarterly analysis of 3 years shows Soleno Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.56 in 2014, then decreased by 2.56% to -$1.60 in 2015, then soared by 86.88% to -$0.21 in 2016.
- Its EPS (Weighted Average and Diluted) stands at -$0.21 for Q2 2016, versus -$1.60 for Q2 2015 and -$1.56 for Q2 2014.
